+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Healthcare Licensing Trends: Norway

  • ID: 4861658
  • Report
  • September 2019
  • Region: Global, Norway
  • 61 Pages
  • FinGlobe, Inc

FEATURED COMPANIES

  • Aqua Bio Technology ASA
  • Inven2
  • Navamedic ASA
  • OncoImmunity AS
  • PCI Biotech Holding ASA
  • Targovax ASA
  • MORE
This trends report provides comprehensive analysis on all licensing deals and negotiations reported for the healthcare companies of Norway during January 1, 2018 to August 31, 2019, categorized and summarized by various important aspects such as healthcare sub-sectors, market capitalization groups, medicine groups, across key regions, licensing payment arrangements, and worldwide vs domestic licensing. Such detailed analysis helps to understand the licensing trends and directions during this time period in the healthcare segments of Norway.

Analytical data coverage:
  • January 1, 2018 to August 31, 2019 licensing deals and negotiations
  • 40+ healthcare licensing news of 20+ companies of Norway
  • Small-mid-large cap companies covered
  • Listed and non-listed companies included
  • 4 healthcare sub-sectors covered-Pharmaceuticals (32%), Biotech (32%), Medical Devices (9%), Healthcare Services (27%)
  • 14 medicine groups studied-Oncology (29%), Infectious Disease (18%), Dermatology and Endocrinology (10% each)
  • 8+ variables analyzed
Key Features:
  • 20 months’ healthcare licensing transactions of Norway analyzed at one place
  • Small, medium and big multinational/non-multinational companies covered
  • Curated categorizations of licensing details
  • Licensing trends and directions summarized
The Report is useful to:
  • Healthcare companies of Norway planning to introduce products in other countries
  • Companies active in R&D and seeking new market base
  • Healthcare company executives of Norway negotiating licensing deals
  • Investors analyzing varied kinds of transaction options for licensing deals in Norway
Key analysis provided: January 2018-August 2019
  • Total number of licensing deals signed by companies of Norway
  • Total number of companies/institutes of Norway involved in the licensing deals
  • Most licensing deals signed by companies of which sub-industry within healthcare sector
  • Most licensing deals signed by which market capitalization group’s companies
  • Most licensing deals signed by which medicine groups
  • Licensing payment arrangements most followed in the licensing deals
  • Number of domestic and worldwide licensing
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aqua Bio Technology ASA
  • Inven2
  • Navamedic ASA
  • OncoImmunity AS
  • PCI Biotech Holding ASA
  • Targovax ASA
  • MORE
Introduction
Research Design

Chapter 1: Analysis of healthcare inventions of Norway licensed during last twenty months
1.1 Healthcare sub-sectors with most licensing deals
1.2 Market capitalization groups with most licensing deals
1.3 Medicine groups most active in licensing deals
1.4 Licensing payment arrangements most followed
1.5 Worldwide licensing vs domestic licensing

Chapter 2: Analysis of licensing deals of Norway by key attributes during last twenty months
2.1 For each of the healthcare sub-sectors
2.2 For each of the marketcap groups
2.3 For each of the medicine groups
2.4 Across each of the regions

Chapter 3: Summary and conclusions

Appendices
Appendix 1 Healthcare inventions licensed for Norway during last twenty months - By company name
Appendix 2 List of companies/institutes covered - By company name
Appendix 3 List of companies/institutes covered - By sub-industry and company name
Appendix 4 List of companies/institutes covered - By market capitalization group and company name
Appendix 5 List of non-listed companies covered - By company name
Appendix 6 List of not-for-profit groups covered - By institute name
Appendix 7 List of companies/institutes covered - By medicine group and company name
Appendix 8 List of companies/institutes covered - By terms of payment and company name
Appendix 9 Licensing deals discontinued for Norway during last twenty months
Note: Product cover images may vary from those shown
  • Aqua Bio Technology ASA
  • Biotec Pharmacon ASA
  • Coalition for Epidemic Preparedness Innovations
  • Ecobrands AS
  • Haukeland University Hospital
  • Institute of Energy Technology
  • Inven2
  • Kappa Bioscience AS
  • NattoPharma ASA
  • Navamedic ASA
  • Nordic Bioscience A/S
  • Nordic Nanovector ASA
  • OncoImmunity AS
  • Oncoinvent AS
  • Oslo University Hospital
  • PCI Biotech Holding ASA
  • Photocure ASA
  • Serca Pharmaceuticals AS
  • Targovax ASA
  • Ultimovacs AS
  • University of Oslo
  • Zelluna Immunotherapy AS
Note: Product cover images may vary from those shown
Adroll
adroll